

Paul M Tulkens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5803907/publications.pdf>

Version: 2024-02-01

197
papers

14,227
citations

23567

58
h-index

22166

113
g-index

199
all docs

199
docs citations

199
times ranked

13712
citing authors

#	ARTICLE	IF	CITATIONS
1	Population Pharmacokinetics of Temocillin Administered by Continuous Infusion in Patients with Septic Shock Associated with Intra-Abdominal Infection and Ascitic Fluid Effusion. <i>Antibiotics</i> , 2022, 11, 898.	3.7	4
2	In Vitro Models for the Study of the Intracellular Activity of Antibiotics. <i>Methods in Molecular Biology</i> , 2021, 2357, 239-251.	0.9	2
3	Clinical Use and Adverse Drug Reactions of Linezolid: A Retrospective Study in Four Belgian Hospital Centers. <i>Antibiotics</i> , 2021, 10, 530.	3.7	20
4	Uropathogenic <i>Escherichia coli</i> Shows Antibiotic Tolerance and Growth Heterogeneity in an <i>In Vitro</i> Model of Intracellular Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0146821.	3.2	7
5	Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, iv9-iv22.	3.0	2
6	Activity of Moxifloxacin Against Biofilms Formed by Clinical Isolates of <i>Staphylococcus aureus</i> Differing by Their Resistant or Persister Character to Fluoroquinolones. <i>Frontiers in Microbiology</i> , 2021, 12, 785573.	3.5	5
7	Comparative in vitro antimicrobial potency, stability, colouration and dissolution time of generics versus innovator of meropenem in Europe. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105825.	2.5	7
8	Antibiotic Resistance, Biofilm Formation, and Intracellular Survival As Possible Determinants of Persistent or Recurrent Infections by <i>Staphylococcus aureus</i> in a Vietnamese Tertiary Hospital: Focus on Bacterial Response to Moxifloxacin. <i>Microbial Drug Resistance</i> , 2020, 26, 537-544.	2.0	16
9	Cellular pharmacokinetics and intracellular activity of the bacterial fatty acid synthesis inhibitor, afabicin desphosphono against different resistance phenotypes of <i>Staphylococcus aureus</i> in models of cultured phagocytic cells. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105848.	2.5	6
10	The Persister Character of Clinical Isolates of <i>Staphylococcus aureus</i> Contributes to Faster Evolution to Resistance and Higher Survival in THP-1 Monocytes: A Study With Moxifloxacin. <i>Frontiers in Microbiology</i> , 2020, 11, 587364.	3.5	11
11	Phosphocholine May Allow for Listeriolysin-Mediated Escape of Phagocytized <i>Listeria</i> From Vacuolar Compartments Into the Host Cytosol While Protecting Against Overt Destruction of the Infected Cell. <i>Journal of Infectious Diseases</i> , 2020, 222, 1425-1427.	4.0	0
12	Prolonged inhibition and incomplete recovery of mitochondrial function in oxazolidinone-treated megakaryoblastic cell lines. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 661-667.	2.5	3
13	Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 702-708.	2.5	16
14	Profile of a Novel Anionic Fluoroquinolone—Delafloxacin. <i>Clinical Infectious Diseases</i> , 2019, 68, S213-S222.	5.8	44
15	Temocillin plasma and pancreatic tissue concentrations in a critically ill patient with septic shock. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1459-1461.	3.0	2
16	Development of clinical pharmacy in Belgian hospitals through pilot projects funded by the government. <i>Acta Clinica Belgica</i> , 2019, 74, 75-81.	1.2	9
17	Antiretroviral-induced adverse drug reactions in HIV-infected patients in Mali: a resource-limited setting experience. <i>International Journal of Basic and Clinical Pharmacology</i> , 2019, 8, 831.	0.1	5
18	Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against <i>Staphylococcus aureus</i> Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	14

#	ARTICLE	IF	CITATIONS
19	Mitochondrial Alterations (Inhibition of Mitochondrial Protein Expression, Oxidative Metabolism,) Tj ETQq1 1 0.784314 rgBT /Overloc Cultured Human HL-60 Promyelocytes and THP-1 Monocytes. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
20	Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in <i>In Vitro</i> Static and Dynamic Models. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	19
21	Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations. Journal of Antimicrobial Chemotherapy, 2018, 73, 1630-1638.	3.0	4
22	Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis. International Journal of Antimicrobial Agents, 2018, 52, 697-701.	2.5	47
23	The Putative De-N-acetylase DnpA Contributes to Intracellular and Biofilm-Associated Persistence of Pseudomonas aeruginosa Exposed to Fluoroquinolones. Frontiers in Microbiology, 2018, 9, 1455.	3.5	6
24	Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic. Scientific Reports, 2017, 7, 40208.	3.3	34
25	Salicylidene Acylhydrazides and Hydroxyquinolines Act as Inhibitors of Type Three Secretion Systems in Pseudomonas aeruginosa by Distinct Mechanisms. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	33
26	Acquired resistance to macrolides in<i>Pseudomonas aeruginosa</i>from cystic fibrosis patients. European Respiratory Journal, 2017, 49, 1601847.	6.7	42
27	Optimizing Î²-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?. Expert Review of Anti-Infective Therapy, 2017, 15, 677-688.	4.4	77
28	Mechanisms of Action. , 2017, , 1162-1180.e1.		30
29	Subcellular mechanisms involved in apoptosis induced by aminoglycoside antibiotics: Insights on p53, proteasome and endoplasmic reticulum. Toxicology and Applied Pharmacology, 2016, 309, 24-36.	2.8	15
30	Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe. Antimicrobial Agents and Chemotherapy, 2016, 60, 6735-6741.	3.2	43
31	Inhibition of the Injectisome and Flagellar Type III Secretion Systems by INP1855 Impairs<i>Pseudomonas aeruginosa</i><i>Pathogenicity and Inflammasome Activation. Journal of Infectious Diseases, 2016, 214, 1105-1116.	4.0	26
32	The antifungal caspofungin increases fluoroquinolone activity against Staphylococcus aureus biofilms by inhibiting N-acetylglucosamine transferase. Nature Communications, 2016, 7, 13286.	12.8	41
33	High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations. International Journal of Antimicrobial Agents, 2016, 48, 740-743.	2.5	55
34	Modulating antibiotic activity towards respiratory bacterial pathogens by co-medications: a multi-target approach. Drug Discovery Today, 2016, 21, 1114-1129.	6.4	12
35	The role of solithromycin in the management of bacterial community-acquired pneumonia. Expert Review of Anti-Infective Therapy, 2016, 14, 311-324.	4.4	17
36	<i>Editorial Commentary</i>: Colistin and a New Paradigm in Drug Development. Clinical Infectious Diseases, 2016, 62, 559-560.	5.8	3

#	ARTICLE	IF	CITATIONS
37	Increase of efflux-mediated resistance in <i>Pseudomonas aeruginosa</i> during antibiotic treatment in patients suffering from nosocomial pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 77-83.	2.5	20
38	In Vitro Models for the Study of the Intracellular Activity of Antibiotics. <i>Methods in Molecular Biology</i> , 2016, 1333, 147-157.	0.9	12
39	Molecular Analysis of Rising Fluoroquinolone Resistance in Belgian Non-Invasive <i>Streptococcus pneumoniae</i> Isolates (1995-2014). <i>PLoS ONE</i> , 2016, 11, e0154816.	2.5	11
40	Activities of Antibiotic Combinations against Resistant Strains of <i>Pseudomonas aeruginosa</i> in a Model of Infected THP-1 Monocytes. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 258-268.	3.2	17
41	Thrice-weekly temocillin administered after each dialysis session is appropriate for the treatment of serious Gram-negative infections in haemodialysis patients. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 660-665.	2.5	5
42	Avibactam confers susceptibility to a large proportion of ceftazidime-resistant <i>Pseudomonas aeruginosa</i> isolates recovered from cystic fibrosis patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1596-1598.	3.0	27
43	Modulation of the activity of moxifloxacin and solithromycin in an in vitro pharmacodynamic model of <i>Streptococcus pneumoniae</i> naive and induced biofilms. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1713-26.	3.0	4
44	Validation of a HPLC-MS/MS assay for the determination of total and unbound concentration of temocillin in human serum. <i>Clinical Biochemistry</i> , 2015, 48, 542-545.	1.9	12
45	RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (<i>Staphylococcus aureus</i>) and Gram-Negative (<i>Pseudomonas aeruginosa</i>) Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4750-4758.	3.2	1
46	Correlation between cytotoxicity induced by <i>Pseudomonas aeruginosa</i> clinical isolates from acute infections and IL-1 β secretion in a model of human THP-1 monocytes. <i>Pathogens and Disease</i> , 2015, 73, ftv049.	2.0	16
47	Cellular Pharmacokinetics and Intracellular Activity of the Novel Peptide Deformylase Inhibitor GSK1322322 against <i>Staphylococcus aureus</i> Laboratory and Clinical Strains with Various Resistance Phenotypes: Studies with Human THP-1 Monocytes and J774 Murine Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5747-5760.	3.2	16
48	Nonclinical and Pharmacokinetic Assessments To Evaluate the Potential of Tedizolid and Linezolid To Affect Mitochondrial Function. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 178-185.	3.2	77
49	Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 891-898.	3.0	71
50	Antibiotic Activity against Naive and Induced <i>Streptococcus pneumoniae</i> Biofilms in an In Vitro Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1348-1358.	3.2	18
51	Tedizolid Phosphate for the Management of Acute Bacterial Skin and Skin Structure Infections: Safety Summary. <i>Clinical Infectious Diseases</i> , 2014, 58, S51-S57.	5.8	36
52	Study of Macrophage Functions in Murine J774 Cells and Human Activated THP-1 Cells Exposed to Oritavancin, a Lipoglycopeptide with High Cellular Accumulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2059-2066.	3.2	19
53	Development and validation of a high performance liquid chromatography assay for the determination of temocillin in serum of haemodialysis patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 90, 192-197.	2.8	11
54	Characterisation of a collection of <i>Streptococcus pneumoniae</i> isolates from patients suffering from acute exacerbations of chronic bronchitis: In vitro susceptibility to antibiotics and biofilm formation in relation to antibiotic efflux and serotypes/serogroups. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 209-217.	2.5	10

#	ARTICLE	IF	CITATIONS
55	Comparison of the Antibiotic Activities of Daptomycin, Vancomycin, and the Investigational Fluoroquinolone Delafloxacin against Biofilms from <i>Staphylococcus aureus</i> Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6385-6397.	3.2	88
56	Pharmacological Characterization of 7-(4-(Piperazin-1-yl)) Ciprofloxacin Derivatives: Antibacterial Activity, Cellular Accumulation, Susceptibility to Efflux Transporters, and Intracellular Activity. <i>Pharmaceutical Research</i> , 2014, 31, 1290-1301.	3.5	20
57	Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 439-446.	2.5	40
58	Antibiotic activity against small-colony variants of <i>Staphylococcus aureus</i> : review of in vitro, animal and clinical data. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1455-1464.	3.0	154
59	Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant <i>Staphylococcus aureus</i> : comparison with vancomycin, linezolid and daptomycin. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 648-658.	3.0	16
60	Stability and compatibility of vancomycin for administration by continuous infusion. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1179-1182.	3.0	50
61	A Combined Pharmacodynamic Quantitative and Qualitative Model Reveals the Potent Activity of Daptomycin and Delafloxacin against <i>Staphylococcus aureus</i> Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2726-2737.	3.2	114
62	Pharmacodynamic Evaluation of the Intracellular Activity of Antibiotics towards <i>Pseudomonas aeruginosa</i> PAO1 in a Model of THP-1 Human Monocytes. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2310-2318.	3.2	49
63	Analysis of the Membrane Proteome of Ciprofloxacin-Resistant Macrophages by Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC). <i>PLoS ONE</i> , 2013, 8, e58285.	2.5	8
64	Increased Susceptibility of <i>Pseudomonas aeruginosa</i> to Macrolides and Ketolides in Eukaryotic Cell Culture Media and Biological Fluids Due to Decreased Expression of oprM and Increased Outer-Membrane Permeability. <i>Clinical Infectious Diseases</i> , 2012, 55, 534-542.	5.8	90
65	Macrophage Killing of Bacterial and Fungal Pathogens Is Not Inhibited by Intense Intracellular Accumulation of the Lipoglycopeptide Antibiotic Oritavancin. <i>Clinical Infectious Diseases</i> , 2012, 54, S229-S232.	5.8	21
66	Influence of the Protein Kinase C Activator Phorbol Myristate Acetate on the Intracellular Activity of Antibiotics against Hemin- and Menadione-Auxotrophic Small-Colony Variant Mutants of <i>Staphylococcus aureus</i> and Their Wild-Type Parental Strain in Human THP-1 Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6166-6174.	3.2	13
67	Role of MexAB-OprM in intrinsic resistance of <i>Pseudomonas aeruginosa</i> to temocillin and impact on the susceptibility of strains isolated from patients suffering from cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 771-775.	3.0	16
68	Intracellular forms of menadione-dependent small-colony variants of methicillin-resistant <i>Staphylococcus aureus</i> are hypersusceptible to β -lactams in a THP-1 cell model due to cooperation between vacuolar acidic pH and oxidant species. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2873-2881.	3.0	15
69	Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells. <i>Peptides</i> , 2012, 35, 248-252.	2.4	39
70	Antimicrobial susceptibility of <i>Streptococcus pneumoniae</i> isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 208-216.	2.5	8
71	Moxifloxacin Safety. <i>Drugs in R and D</i> , 2012, 12, 71-100.	2.2	45
72	Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?. <i>Annals of Intensive Care</i> , 2012, 2, 22.	4.6	41

#	ARTICLE	IF	CITATIONS
73	Content Validity and Inter-Rater Reliability of an Instrument to Characterize Unintentional Medication Discrepancies. <i>Drugs and Aging</i> , 2012, 29, 577-591.	2.7	9
74	Adverse Drug Reactions to Antiretroviral Therapy: Prospective Study in Children in Sikasso (Mali). <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2012, 17, 382-388.	0.5	9
75	Hepatic safety of antibiotics used in primary care. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1431-1446.	3.0	154
76	Activity of Fusidic Acid Against Extracellular and Intracellular <i>Staphylococcus aureus</i> : Influence of pH and Comparison With Linezolid and Clindamycin. <i>Clinical Infectious Diseases</i> , 2011, 52, S493-S503.	5.8	31
77	Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular <i>Staphylococcus aureus</i> , <i>Listeria monocytogenes</i> and <i>Legionella pneumophila</i> . <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 52-59.	2.5	52
78	Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 249-56.	2.5	34
79	Long-term stability of temocillin in dextrose 5% and in sodium chloride 0.9% polyolefin bags at $5\pm 3^{\circ}\text{C}$ after freeze-thaw treatment. <i>Annales Pharmaceutiques Francaises</i> , 2011, 69, 296-301.	1.0	7
80	Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 649-658.	3.2	160
81	Tackling antibiotic resistance. <i>Nature Reviews Microbiology</i> , 2011, 9, 894-896.	28.6	919
82	Modulation of the expression of ABC transporters in murine (J774) macrophages exposed to large concentrations of the fluoroquinolone antibiotic moxifloxacin. <i>Toxicology</i> , 2011, 290, 178-186.	4.2	9
83	Role of oxidative stress in lysosomal membrane permeabilization and apoptosis induced by gentamicin, an aminoglycoside antibiotic. <i>Free Radical Biology and Medicine</i> , 2011, 51, 1656-1665.	2.9	91
84	Intra- and Extracellular Activities of Dicloxacillin and Linezolid against a Clinical <i>Staphylococcus aureus</i> Strain with a Small-Colony-Variant Phenotype in an In Vitro Model of THP-1 Macrophages and an In Vivo Mouse Peritonitis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1443-1452.	3.2	19
85	Activity of moxifloxacin against intracellular community-acquired methicillin-resistant <i>Staphylococcus aureus</i> : comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 596-607.	3.0	32
86	Efflux of novel quinolones in contemporary <i>Streptococcus pneumoniae</i> isolates from community-acquired pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 948-951.	3.0	3
87	Characterization of Abcc4 Gene Amplification in Stepwise-Selected Mouse J774 Macrophages Resistant to the Topoisomerase II Inhibitor Ciprofloxacin. <i>PLoS ONE</i> , 2011, 6, e28368.	2.5	12
88	Cellular Pharmacokinetics of the Novel Biarylloxazolidinone Radezolid in Phagocytic Cells: Studies with Macrophages and Polymorphonuclear Neutrophils. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2540-2548.	3.2	73
89	Activity of quinupristin/dalfopristin against extracellular and intracellular <i>Staphylococcus aureus</i> with various resistance phenotypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1228-1236.	3.0	15
90	Intracellular activity of the peptide antibiotic NZ2114: studies with <i>Staphylococcus aureus</i> and human THP-1 monocytes, and comparison with daptomycin and vancomycin. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1720-1724.	3.0	41

#	ARTICLE	IF	CITATIONS
91	Long-term stability of temocillin in elastomeric pumps for outpatient antibiotic therapy in cystic fibrosis patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2045-2046.	3.0	15
92	Cellular Pharmacodynamics of the Novel Biarylloxazolidinone Radezolid: Studies with Infected Phagocytic and Nonphagocytic cells, Using <i>Staphylococcus aureus</i> , <i>Staphylococcus epidermidis</i> , <i>Listeria monocytogenes</i> , and <i>Legionella pneumophila</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2549-2559.	3.2	58
93	Intra- and extracellular activity of linezolid against <i>Staphylococcus aureus</i> in vivo and in vitro. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 962-973.	3.0	24
94	Intra- and Extracellular Activities of Dicloxacillin against <i>Staphylococcus aureus</i> In Vivo and In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2391-2400.	3.2	21
95	In vivo development of antimicrobial resistance in <i>Pseudomonas aeruginosa</i> strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 513-522.	2.5	72
96	Fluoroquinolones induce the expression of patA and patB, which encode ABC efflux pumps in <i>Streptococcus pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2076-2082.	3.0	50
97	Stability of meropenem and doripenem solutions for administration by continuous infusion. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1073-1075.	3.0	100
98	Dynamics and Structural Changes Induced by ATP Binding in SAV1866, a Bacterial ABC Exporter. <i>Journal of Physical Chemistry B</i> , 2010, 114, 15948-15957.	2.6	43
99	Mechanisms of action. , 2010, , 1288-1307.		0
100	Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 1035-1043.	3.0	59
101	Plectasin Shows Intracellular Activity against <i>Staphylococcus aureus</i> in Human THP-1 Monocytes and in a Mouse Peritonitis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4801-4808.	3.2	59
102	Activities of Ceftobiprole and Other Cephalosporins against Extracellular and Intracellular (THP-1) <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2289-2297.	3.2	41
103	Identification of the Efflux Transporter of the Fluoroquinolone Antibiotic Ciprofloxacin in Murine Macrophages: Studies with Ciprofloxacin-Resistant Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2410-2416.	3.2	26
104	Cellular Accumulation and Pharmacodynamic Evaluation of the Intracellular Activity of CEM-101, a Novel Fluoroketolide, against <i>Staphylococcus aureus</i> , <i>Listeria monocytogenes</i> , and <i>Legionella pneumophila</i> in Human THP-1 Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3734-3743.	3.2	53
105	Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a <i>Staphylococcus aureus</i> Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Study of Antibiotic Combinations. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1443-1449.	3.2	37
106	Role of <i>Staphylococcus aureus</i> and Staphyloxanthin in Phagocytosis and Intracellular Growth of <i>Staphylococcus aureus</i> in Human Macrophages and Endothelial Cells. <i>Journal of Infectious Diseases</i> , 2009, 200, 1367-1370.	4.0	39
107	Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a <i>Staphylococcus aureus</i> Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Pharmacodynamic Evaluation and Comparison with Isogenic Normal-Phenotype and Revertant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1434-1442.	3.2	54
108	Isolation and 2D DIGE proteomic analysis of intracellular and extracellular forms of <i>Listeria monocytogenes</i> . <i>Proteomics</i> , 2009, 9, 5484-5496.	2.2	18

#	ARTICLE	IF	CITATIONS
109	Molecular models of human P-glycoprotein in two different catalytic states. <i>BMC Structural Biology</i> , 2009, 9, 3.	2.3	63
110	Penicillin-binding Proteins (PBP) and Lmo0441 (a PBP-like protein) play a role in Beta-lactam sensitivity of <i>Listeria monocytogenes</i> . <i>Gut Pathogens</i> , 2009, 1, 23.	3.4	10
111	Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2009, 1788, 1832-1840.	2.6	77
112	Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 555-560.	2.5	55
113	Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin. <i>Drug Safety</i> , 2009, 32, 359-378.	3.2	108
114	The bacterial envelope as a target for novel anti-MRSA antibiotics. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 124-134.	8.7	129
115	Interactions of ciprofloxacin with DPPC and DPPG: Fluorescence anisotropy, ATR-FTIR and ³¹ P NMR spectroscopies and conformational analysis. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2008, 1778, 2535-2543.	2.6	78
116	Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 267-283.	1.8	37
117	Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 382-388.	3.0	78
118	Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic Tj ETQq0 0 0 rgBT /Osclock 108Tf 50 377		
119	Restoration of Susceptibility of Methicillin-resistant <i>Staphylococcus aureus</i> to β -Lactam Antibiotics by Acidic pH. <i>Journal of Biological Chemistry</i> , 2008, 283, 12769-12776.	3.4	41
120	Cooperation between Prokaryotic (Lde) and Eukaryotic (MRP) Efflux Transporters in J774 Macrophages Infected with <i>Listeria monocytogenes</i> : Studies with Ciprofloxacin and Moxifloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3040-3046.	3.2	26
121	Apoptosis Induced by Aminoglycosides in LLC-PK1 Cells: Comparative Study of Neomycin, Gentamicin, Amikacin, and Isepamicin Using Electroporation. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2236-2238.	3.2	16
122	Temocillin revived. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 243-245.	3.0	107
123	Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against <i>Staphylococcus aureus</i> and <i>Listeria monocytogenes</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 518-521.	3.0	18
124	Restoration of Susceptibility of Intracellular Methicillin-Resistant <i>Staphylococcus aureus</i> to β -Lactams: Comparison of Strains, Cells, and Antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2797-2805.	3.2	26
125	Tissue concentrations: do we ever learn?. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 235-237.	3.0	333
126	A combined phenotypic and genotypic method for the detection of Mex efflux pumps in <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 378-386.	3.0	78

#	ARTICLE	IF	CITATIONS
127	Selection of quinolone resistance in <i>Streptococcus pneumoniae</i> exposed in vitro to subinhibitory drug concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 965-972.	3.0	42
128	Role of Acidic pH in the Susceptibility of Intraphagocytic Methicillin-Resistant <i>Staphylococcus aureus</i> Strains to Meropenem and Cloxacillin. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1627-1632.	3.2	32
129	Multidrug-Resistant <i>Streptococcus pneumoniae</i> Infections. <i>Drugs</i> , 2007, 67, 2355-2382.	10.9	104
130	<i>Pseudomonas aeruginosa</i> : r�sistance et options th�rapeutiques � l'�mbe du deuxi�me mill�naire. <i>Antibiotiques</i> , 2007, 9, 189-198.	0.1	3
131	Modulation of the Cellular Accumulation and Intracellular Activity of Daptomycin towards Phagocytized <i>Staphylococcus aureus</i> by the P-Glycoprotein (MDR1) Efflux Transporter in Human THP-1 Macrophages and Madin-Darby Canine Kidney Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2748-2757.	3.2	53
132	Design and evaluation of analogues of the bacterial cell-wall peptidoglycan motif L-Lys-d-Ala-d-Ala for use in a vancomycin biosensor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 5758-5762.	2.2	4
133	Effect of a Collaborative Approach on the Quality of Prescribing for Geriatric Inpatients: A Randomized, Controlled Trial. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 658-665.	2.6	262
134	Predicting the three-dimensional structure of human P-glycoprotein in absence of ATP by computational techniques embodying crosslinking data: Insight into the mechanism of ligand migration and binding sites. <i>Proteins: Structure, Function and Bioinformatics</i> , 2006, 63, 466-478.	2.6	28
135	Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 1177-1184.	3.0	100
136	Gentamicin Causes Apoptosis at Low Concentrations in Renal LLC-PK 1 Cells Subjected to Electroporation. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1213-1221.	3.2	73
137	Cellular Accumulation and Activity of Quinolones in Ciprofloxacin-Resistant J774 Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1689-1695.	3.2	24
138	Implementation of Ward-Based Clinical Pharmacy Services in Belgium�Description of the Impact on a Geriatric Unit. <i>Annals of Pharmacotherapy</i> , 2006, 40, 720-728.	1.9	85
139	Water-soluble amphotericin B�polyvinylpyrrolidone complexes with maintained antifungal activity against <i>Candida</i> spp. and <i>Aspergillus</i> spp. and reduced haemolytic and cytotoxic effects. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 236-244.	3.0	52
140	Combined effect of pH and concentration on the activities of gentamicin and oxacillin against <i>Staphylococcus aureus</i> in pharmacodynamic models of extracellular and intracellular infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 59, 246-253.	3.0	87
141	Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against <i>Staphylococcus aureus</i> in a Model of THP-1 Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 841-851.	3.2	228
142	Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. <i>Current Opinion in Drug Discovery & Development</i> , 2006, 9, 218-30.	1.9	55
143	Modulation of the in vitro activity of lysosomal phospholipase A1 by membrane lipids. <i>Chemistry and Physics of Lipids</i> , 2005, 133, 1-15.	3.2	21
144	Gentamicin-induced apoptosis in LLC-PK1 cells: Involvement of lysosomes and mitochondria. <i>Toxicology and Applied Pharmacology</i> , 2005, 206, 321-333.	2.8	124

#	ARTICLE	IF	CITATIONS
145	Mixed-Lipid Storage Disorder Induced in Macrophages and Fibroblasts by Oritavancin (LY333328), a New Glycopeptide Antibiotic with Exceptional Cellular Accumulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1695-1700.	3.2	32
146	Activity of three β -lactams (ertapenem, meropenem and ampicillin) against intraphagocytic <i>Listeria monocytogenes</i> and <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 897-904.	3.0	50
147	Accumulation and Oriented Transport of Ampicillin in Caco-2 Cells from Its Pivaloyloxymethylester Prodrug, Pivampicillin. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1279-1288.	3.2	19
148	Appropriateness of use of medicines in elderly inpatients: qualitative study. <i>BMJ: British Medical Journal</i> , 2005, 331, 935.	2.3	81
149	Influence of Efflux Transporters on the Accumulation and Efflux of Four Quinolones (Ciprofloxacin,) Tj ETQq1 1 0.784314 rgBT /Overlo Chemotherapy, 2005, 49, 2429-2437.	3.2	76
150	Impairment of Growth of <i>Listeria monocytogenes</i> in THP-1 Macrophages by Granulocyte Macrophage Colony-Stimulating Factor: Release of Tumor Necrosis Factor- α and Nitric Oxide. <i>Journal of Infectious Diseases</i> , 2004, 189, 2101-2109.	4.0	29
151	Inhibition of TNF- α production in THP-1 macrophages by glatiramer acetate does not alter their susceptibility to infection by <i>Listeria monocytogenes</i> and does not impair the efficacy of ampicillin or moxifloxacin against intracellular bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 288-289.	3.0	1
152	Association Between Antibiotic Sales and Public Campaigns for Their Appropriate Use. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 2465.	7.4	43
153	Active Efflux of Ciprofloxacin from J774 Macrophages through an MRP-Like Transporter. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2673-2682.	3.2	52
154	Cellular Pharmacokinetics and Pharmacodynamics of the Glycopeptide Antibiotic Oritavancin (LY333328) in a Model of J774 Mouse Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2853-2860.	3.2	66
155	Cocaine induces a mixed lysosomal lipidosis in cultured fibroblasts, by inactivation of acid sphingomyelinase and inhibition of phospholipase A1. <i>Toxicology and Applied Pharmacology</i> , 2004, 194, 101-110.	2.8	17
156	Glycopeptide Antibiotics. <i>Drugs</i> , 2004, 64, 913-936.	10.9	181
157	Cell handling, membrane-binding properties, and membrane-penetration modeling approaches of pivampicillin and phthalimidomethylampicillin, two basic esters of ampicillin, in comparison with chloroquine and azithromycin. <i>Pharmaceutical Research</i> , 2003, 20, 624-631.	3.5	15
158	Intracellular pharmacodynamics of antibiotics. <i>Infectious Disease Clinics of North America</i> , 2003, 17, 615-634.	5.1	164
159	Quantitative Analysis of Gentamicin, Azithromycin, Telithromycin, Ciprofloxacin, Moxifloxacin, and Oritavancin (LY333328) Activities against Intracellular <i>Staphylococcus aureus</i> in Mouse J774 Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2283-2292.	3.2	140
160	Influence of P-Glycoprotein Inhibitors on Accumulation of Macrolides in J774 Murine Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1047-1051.	3.2	64
161	Activity of beta-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular <i>Listeria monocytogenes</i> in a 24 h THP-1 human macrophage model. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 1051-1052.	3.0	40
162	Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by <i>Listeria monocytogenes</i> or <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 1167-1173.	3.0	101

#	ARTICLE	IF	CITATIONS
163	Intracellular accumulation and activity of ampicillin used as freedrug and as its phthalimidomethyl or pivaloyloxymethyl ester (pivampicillin) against <i>Listeria monocytogenes</i> in J774 macrophages. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 610-615.	3.0	8
164	Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 651-658.	3.0	60
165	Comparative Stability Studies of Antipseudomonal β -Lactams for Potential Administration through Portable Elastomeric Pumps (Home Therapy for Cystic Fibrosis Patients) and Motor-Operated Syringes (Intensive Care Units). <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 2327-2332.	3.2	178
166	Comparative Intracellular (THP-1 Macrophage) and Extracellular Activities of β -Lactams, Azithromycin, Gentamicin, and Fluoroquinolones against <i>Listeria monocytogenes</i> at Clinically Relevant Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 2095-2103.	3.2	116
167	Azithromycin, a Lysosomotropic Antibiotic, Has Distinct Effects on Fluid-Phase and Receptor-Mediated Endocytosis, but Does Not Impair Phagocytosis in J774 Macrophages. <i>Experimental Cell Research</i> , 2002, 281, 86-100.	2.6	76
168	Syntheses and hydrolysis of basic and dibasic ampicillin esters tailored for intracellular accumulation. <i>Bioorganic and Medicinal Chemistry</i> , 2001, 9, 493-502.	3.0	13
169	Azithromycin, a lysosomotropic antibiotic, impairs fluid-phase pinocytosis in cultured fibroblasts. <i>European Journal of Cell Biology</i> , 2001, 80, 466-478.	3.6	35
170	Stability and Compatibility of Ceftazidime Administered by Continuous Infusion to Intensive Care Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2643-2647.	3.2	55
171	Antibiotic efflux pumps. <i>Biochemical Pharmacology</i> , 2000, 60, 457-470.	4.4	327
172	Apoptosis in Renal Proximal Tubules of Rats Treated with Low Doses of Aminoglycosides. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 665-675.	3.2	116
173	Aminoglycosides: Nephrotoxicity. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1003-1012.	3.2	686
174	Aminoglycosides: Activity and Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 727-737.	3.2	762
175	Mechanism of the Intracellular Killing and Modulation of Antibiotic Susceptibility of <i>Listeria monocytogenes</i> in THP-1 Macrophages Activated by Gamma Interferon. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1242-1251.	3.2	59
176	Modulation of Intracellular Growth of <i>Listeria monocytogenes</i> in Human Enterocyte Caco-2 Cells by Interferon- γ and Interleukin-6: Role of Nitric Oxide and Cooperation with Antibiotics. <i>Journal of Infectious Diseases</i> , 1999, 180, 1195-1204.	4.0	17
177	Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional tissue accumulation. <i>FEBS Letters</i> , 1996, 394, 307-310.	2.8	19
178	Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. <i>European Journal of Pharmacology</i> , 1996, 314, 203-214.	3.5	53
179	Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies. <i>European Journal of Pharmacology</i> , 1996, 314, 215-227.	3.5	35
180	Leupeptin and E-64, inhibitors of cysteine proteinases, prevent gentamicin-induced lysosomal phospholipidosis in cultured rat fibroblasts. <i>Toxicology Letters</i> , 1994, 73, 201-208.	0.8	14

#	ARTICLE	IF	CITATIONS
181	Alterations in membrane permeability induced by aminoglycoside antibiotics: studies on liposomes and cultured cells. <i>European Journal of Pharmacology</i> , 1993, 247, 155-168.	2.6	44
182	Effect of substrate organization on the activity and on the mechanism of gentamicin-induced inhibition of rat liver lysosomal phospholipase A1. <i>Biochemical Pharmacology</i> , 1992, 43, 895-898.	4.4	14
183	Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. <i>Biochemical Pharmacology</i> , 1990, 40, 2383-2392.	4.4	161
184	Effect of acidic phospholipids on the activity of lysosomal phospholipases and on their inhibition by aminoglycoside antibiotics. <i>Biochemical Pharmacology</i> , 1990, 40, 489-497.	4.4	35
185	Ultrastructural, physico-chemical and conformational study of the interactions of gentamicin and bis(beta-diethylaminoethylether)hexestrol with negatively-charged phospholipid layers. <i>Biochemical Pharmacology</i> , 1989, 38, 729-741.	4.4	47
186	Biochemical mechanism of aminoglycoside-induced inhibition of phosphatidylcholine hydrolysis by lysosomal phospholipases. <i>Biochemical Pharmacology</i> , 1988, 37, 591-599.	4.4	65
187	Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. <i>Journal of Antimicrobial Chemotherapy</i> , 1987, 20, 47-56.	3.0	121
188	Experimental studies on nephrotoxicity of aminoglycosides at low doses: Mechanisms and perspectives. <i>American Journal of Medicine</i> , 1986, 80, 105-114.	1.5	94
189	Early effects of gentamicin, tobramycin, and amikacin on the human kidney. <i>Kidney International</i> , 1984, 25, 643-652.	5.2	167
190	Mechanism of aminoglycoside-induced lysosomal phospholipidosis: In vitro and in vivo studies with Gentamicin and Amikacin. <i>Biochemical Pharmacology</i> , 1982, 31, 3861-3870.	4.4	228
191	Comparative toxicity of aminoglycoside antibiotics towards the lysosomes in a cell culture model. <i>Toxicology</i> , 1980, 17, 195-199.	4.2	21
192	Fate of plasma membrane during endocytosis. II. Evidence for recycling (shuttle) of plasma membrane constituents. <i>Journal of Cell Biology</i> , 1979, 82, 466-474.	5.2	143
193	Gentamicin-induced lysosomal phospholipidosis in cultured rat fibroblasts. Quantitative ultrastructural and biochemical study. <i>Laboratory Investigation</i> , 1979, 40, 481-91.	3.7	37
194	The uptake and intracellular accumulation of aminoglycoside antibiotics in lysosomes of cultured rat fibroblasts. <i>Biochemical Pharmacology</i> , 1978, 27, 415-424.	4.4	155
195	Lysosomotropic agents. <i>Biochemical Pharmacology</i> , 1974, 23, 2495-2531.	4.4	1,870
196	ANALYTICAL FRACTIONATION OF HOMOGENATES FROM CULTURED RAT EMBRYO FIBROBLASTS. <i>Journal of Cell Biology</i> , 1974, 63, 383-401.	5.2	142
197	Immunological Inhibition of Lysosome Function. <i>Nature</i> , 1970, 228, 1282-1285.	27.8	35